|
Dr. Hurwitz is an Associate Professor of Medicine at Duke University Medical Center and a medical oncologist at the Duke Comprehensive Cancer Center. Dr. Hurwitz received his medical degree from Jefferson Medical College in Philadelphia Pennsylvania and completed an Internal Medicine residency at Michael Reese Hospital in Chicago Illinois and an Oncology fellowship at Johns Hopkins Oncology Center in Baltimore Maryland. His clinical expertise is in the areas of Phase 1 clinical trials involving new anti cancer drugs drug combinations and combinations of new drugs with radiation and cancers of the gastrointestinal system. His particular interest is in biomarkers related to anti-angiogenesis therapy. He was the lead author on the IFL/bevacizumab study in colorectal cancer. He is associate professor of medicine and the clinical director of the Phase 1 program and co-leader of the GI Oncology program at Duke University Medical Center in Durham North Carolina. He is an author of over 50 peer-reviewed scientific papers published in leading journals. | 